The Top Health Care Venture Capital Deals of October 2007  (November 15, 2007)

Leading the top deals, Simplex Diabetic Supply, a health care services company founded to become a leading provider of diabetic testing supplies, is already among the largest of the Medicare diabetes suppliers. Simplex secured $50 million from New Enterprise Associates and is using the proceeds from the financing to accelerate and execute its acquisition strategy. Paratek Pharmaceuticals, a biopharmaceutical company focused on the worldwide problem of antibiotic resistance, raised $40 million from Aisling Capital, D.E. Shaw, Boston Life Science Ventures, Nomura Phase4Ventures, BioFunds Ventures, HBM BioVentures, Lombard Odier Darier Hentsch and Cie, BioVeda Fund and Hercules Technology Growth Capital. Paratek’s most advanced broad-spectrum antibiotic is being developed to treat serious infections such as complicated skin and skin structure infections and moderate to severe community-acquired pneumonias. Oxford Immunotec, a biotech, also secured $40 million, in its Series C financing. With the proceeds, Oxford Immunotec is launching its lead product in the United States, a highly sensitive and specific blood test for tuberculosis that is already being marketed directly and via distributors in Europe, Canada and other countries. Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Prelude Trust and Quester contributed to investment in Oxford. Biotechnology company Optherion raised $37 million in from Quaker BioVentures, Domain Associates, Johnson & Johnson Development Corporation, Purdue Pharmaceutical Products, Pappas Ventures, Biogen Idec New Ventures and GE Healthcare Financial Services. With the funding from the round, Optherion is developing products to diagnose and treat dry and wet age-related macular degeneration and other chronic diseases, using intellectual property that is based on discoveries made at the University of Iowa, Yale University and Rockefeller University, among others. Metastatix raised the fifth-largest round of the month, with $35 million from Frazier Healthcare Ventures, HIG Ventures, Aurora Funds, CM Capital, S.R. One, MedImmune Ventures, Georgia Venture Partners, Centrosome Ventures and other participating investors. With the proceeds from the round, in which the state of Georgia invested, Metastatix is funding clinical trials of its lead drug candidate in cancer patients and advancing its development programs in inflammation and HIV infection.
 

Click here for a FREE TRIAL to the Healthcare Corporate Finance News

VC Blog Archive

Back to top